Crestline Management LP Acquires New Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Crestline Management LP bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,105 shares of the biopharmaceutical company’s stock, valued at approximately $595,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AGIO. Vanguard Group Inc. grew its stake in shares of Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after purchasing an additional 85,339 shares during the period. Fisher Asset Management LLC grew its position in shares of Agios Pharmaceuticals by 12.3% during the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company’s stock worth $31,567,000 after buying an additional 105,333 shares during the period. ArrowMark Colorado Holdings LLC grew its position in shares of Agios Pharmaceuticals by 3.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company’s stock worth $30,146,000 after buying an additional 34,689 shares during the period. Caligan Partners LP increased its stake in shares of Agios Pharmaceuticals by 8.0% in the 4th quarter. Caligan Partners LP now owns 626,280 shares of the biopharmaceutical company’s stock valued at $20,580,000 after acquiring an additional 46,563 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Agios Pharmaceuticals by 0.9% in the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company’s stock valued at $19,567,000 after acquiring an additional 5,372 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price for the company. Scotiabank dropped their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a research note on Friday, May 2nd. Finally, StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $27.32 on Friday. The business has a 50-day moving average of $29.23 and a 200-day moving average of $37.27. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a market capitalization of $1.58 billion, a P/E ratio of 2.41 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.